Efficacy of rivastigmine in treating mild to severe Alzheimer's disease with different Hachinski ischemia index

王清华,张振馨,许贤豪,舒良,姚景莉,陈生弟,钱采韻,陆雪芬,高之旭

DOI: https://doi.org/10.3760/j.issn:1006-7876.2003.01.013

2003-01-01

Abstract:Objective To evaluate the efficacy of Rivastigmine in treating mild to severe Alzheimer's disease with different Hachinski ischemia index. Methods Totally 211 patients with mild to severe, possible or probable AD were enrolled in a 16-week, 23 centers of 3 cities, open-labeled clinical trial. All patients received Rivastigmine 3.0-4.5 mg bid. Efficacy means included the Alzheimer's Disease Assessment Scale-cognitive Subscale (ADAS-Cog), Mini-Mental State Examination (MMSE) and Blessed-Roth Scale. Results 194 cases had completed the whole trial. In comparing to the baseline, there showed the distinct improvements on MMSE, ADAS-Cog, Blessed-Roth at the 16th week to a whole level (P < 0.0001). In severe patients, the mean change from baseline was improved in 5.4, 0.6, 1.3 points on ADAS-Cog, ability of daily life (B-R1) and interest and personality (B-R3), respectively. All of these were shown higher than in the mild and moderate patients. But the differences among groups were not significant(P > 0.05). The mean score in ADAS-cog, ADL, INT was improved 4.6, 0.4, 1.0 points, respectively. While the baseline for group Hachinski > 0 grade was greater than those in group Hachinski = 0 grade. But the differences between groups were not significant (P > 0.05). Adverse events were shown mostly in the milds happening while dose was increased. Conclusions Rivastigmine showed significant efficacy in the patients with mild to severe AD, which were associated with the cognitive improvements, ability of daily life and psychiatric symptoms. It seems that there should be tendency in severe or Hachinski > 0 grade patients who might be benefited more than in the mild or Hachinski = 0 grade patients.